- Home
- INMB vs MDXH Comparison
INMB vs MDXH Comparison
Compare INMB & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- MDXH
- Stock Information
- Founded
- INMB 2015
- MDXH 2003
- Country
- INMB United States
- MDXH Belgium
- Employees
- INMB N/A
- MDXH N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- MDXH
- Sector
- INMB Health Care
- MDXH
- Exchange
- INMB Nasdaq
- MDXH Nasdaq
- Market Cap
- INMB 112.0M
- MDXH 93.1M
- IPO Year
- INMB 2019
- MDXH 2021
- Fundamental
- Price
- INMB $4.40
- MDXH $2.26
- Analyst Decision
- INMB Strong Buy
- MDXH Strong Buy
- Analyst Count
- INMB 2
- MDXH 2
- Target Price
- INMB $21.00
- MDXH $7.00
- AVG Volume (30 Days)
- INMB 215.6K
- MDXH 137.5K
- Earning Date
- INMB 10-31-2024
- MDXH 11-06-2024
- Dividend Yield
- INMB N/A
- MDXH N/A
- EPS Growth
- INMB N/A
- MDXH N/A
- EPS
- INMB N/A
- MDXH N/A
- Revenue
- INMB $42,000.00
- MDXH $84,708,000.00
- Revenue This Year
- INMB N/A
- MDXH $27.57
- Revenue Next Year
- INMB N/A
- MDXH $20.09
- P/E Ratio
- INMB N/A
- MDXH N/A
- Revenue Growth
- INMB N/A
- MDXH 33.01
- 52 Week Low
- INMB $4.32
- MDXH $1.55
- 52 Week High
- INMB $14.74
- MDXH $4.64
- Technical
- Relative Strength Index (RSI)
- INMB 37.57
- MDXH 57.11
- Support Level
- INMB $4.74
- MDXH $2.12
- Resistance Level
- INMB $5.16
- MDXH $2.52
- Average True Range (ATR)
- INMB 0.38
- MDXH 0.16
- MACD
- INMB -0.05
- MDXH 0.01
- Stochastic Oscillator
- INMB 5.56
- MDXH 61.19
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.